ACOR Acorda Therapeutics, Inc. Stock Quote

ACOR [NASD]

Index	-	P/E	1.18	EPS (ttm)	5.32	Insider Own	1.30%	Shs Outstand	47.71M	Perf Week	-0.63%
Market Cap	62.02M	Forward P/E	-	EPS next Y	-10.35	Insider Trans	0.00%	Shs Float	9.35M	Perf Month	-6.68%
Income	49.10M	PEG	0.04	EPS next Q	-1.48	Inst Own	25.70%	Short Float	8.02%	Perf Quarter	56.98%
Sales	165.30M	P/S	0.38	EPS this Y	23.40%	Inst Trans	-39.10%	Short Ratio	0.67	Perf Half Y	88.45%
Book/sh	6.57	P/B	0.96	EPS next Y	-30.80%	ROA	6.60%	Target Price	-	Perf Year	-14.77%
Cash/sh	6.41	P/C	0.98	EPS next 5Y	29.00%	ROE	16.10%	52W Range	2.53 - 9.84	Perf YTD	51.91%
Dividend	-	P/FCF	-	EPS past 5Y	16.45%	ROI	-48.20%	52W High	-36.08%	Beta	0.56
Dividend %	-	Quick Ratio	0.90	Sales past 5Y	-13.70%	Gross Margin	81.00%	52W Low	148.18%	ATR	0.53
Employees	344	Current Ratio	1.10	Sales Q/Q	11.30%	Oper. Margin	42.30%	RSI (14)	46.21	Volatility	7.47% 7.34%
Optionable	Yes	Debt/Eq	0.73	EPS Q/Q	100.10%	Profit Margin	29.70%	Rel Volume	0.20	Prev Close	6.19
Shortable	Yes	LT Debt/Eq	0.52	Earnings	Mar 04 AMC	Payout	0.00%	Avg Volume	1.12M	Price	6.29
Recom	3.00	SMA20	-9.03%	SMA50	4.00%	SMA200	32.47%	Volume	226,640	Change	1.62%

Aug-14-19

Downgrade

H.C. Wainwright

Buy → Neutral

$31 → $6

May-23-19

Initiated

Wedbush

Neutral

Dec-11-18

Downgrade

Goldman

Neutral → Sell

Aug-07-18

Reiterated

Stifel

Hold

$15 → $25

Feb-16-18

Upgrade

Piper Jaffray

Neutral → Overweight

Jan-17-18

Reiterated

H.C. Wainwright

Buy

$34 → $31

Nov-28-17

Resumed

Piper Jaffray

Neutral

$22

Nov-16-17

Downgrade

Stifel

Buy → Hold

$26 → $15

Nov-16-17

Downgrade

Raymond James

Mkt Perform → Underperform

Nov-09-17

Initiated

Oppenheimer

Perform

Nov-08-17

Initiated

H.C. Wainwright

Buy

$35

Oct-06-17

Resumed

Goldman

Sell

$20

Jul-11-17

Initiated

Jefferies

Hold

Apr-03-17

Downgrade

JP Morgan

Overweight → Neutral

Feb-15-17

Upgrade

Goldman

Sell → Neutral

Nov-30-16

Upgrade

JP Morgan

Neutral → Overweight

Oct-04-16

Resumed

Leerink Partners

Mkt Perform

$25

Mar-30-16

Initiated

Goldman

Sell

Sep-01-15

Initiated

Raymond James

Mkt Perform

Jun-09-15

Initiated

Guggenheim

Neutral

Mar-03-21 12:52PM	Encompass Health (EHC) Ties Up for Better Homehealth Care Zacks
Mar-02-21 08:43AM	Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates Zacks
Feb-26-21 10:10AM	Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall Zacks
Feb-25-21 07:00AM	Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 Business Wire
Feb-19-21 07:00AM	Acorda Therapeutics Announces Departure of Chief, Business Operations Business Wire
Feb-11-21 11:12AM	Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug Zacks
09:13AM	Sesen Bio (SESN) Surges: Stock Moves 6.4% Higher Zacks
07:00AM	Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent Business Wire
Feb-10-21 10:21AM	Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss Zacks -5.85%
Feb-08-21 12:40PM	Acorda (ACOR) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-04-21 11:48AM	Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates Zacks
Feb-02-21 03:23PM	Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B Zacks
10:10AM	Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes Zacks
Feb-01-21 10:28AM	Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib Zacks
10:25AM	Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase Zacks
09:36AM	Illumina (ILMN) New Collaboration to Aid Genomics Startups Zacks
Jan-28-21 10:12AM	Global Blood's (GBT) MAA for Oxbryta Accepted in Europe Zacks
Jan-27-21 11:13AM	Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA Zacks
Jan-25-21 09:28AM	BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo Zacks
Jan-22-21 09:02AM	Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA Zacks +5.26%
Jan-21-21 12:16PM	Novo Nordisk (NVO) Files for Ozempic's Label Expansion in US Zacks -10.20%
Jan-20-21 12:18PM	Cocrystal Pharma (COCP) Completes Research Obligations With Merck Zacks
12:17PM	Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete Zacks
Jan-15-21 08:19PM	Acorda Stock at $35 a Share? This Analyst Thinks Its Possible TipRanks +5.18%
Jan-14-21 12:34PM	Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija Zacks
10:25AM	Company News for Jan 14, 2021 Zacks
Jan-13-21 07:25AM	The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga +44.34%
07:12AM	A Look Into Acorda Therapeutics's Debt Benzinga
07:00AM	Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into "At The Market" Offering Agreement Business Wire
Jan-12-21 04:07PM	Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference Business Wire
Jan-11-21 04:20PM	Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference Business Wire
Dec-31-20 04:19PM	Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split Business Wire
Dec-21-20 12:00PM	What Makes Acorda (ACOR) a New Buy Stock Zacks -5.21%
Dec-07-20 10:22PM	Is ACOR A Good Stock To Buy Now? Insider Monkey
Dec-03-20 08:53AM	Implied Volatility Surging for Acorda (ACOR) Stock Options Zacks
Nov-23-20 10:24AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Nov-16-20 09:48AM	A Look Into Healthcare Sector Value Stocks Benzinga -5.34%
Nov-08-20 07:07AM	Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analysts Are Reducing Their Forecasts For Next Year Simply Wall St.
Nov-03-20 05:15PM	Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:17PM	Acorda Therapeutics: Q3 Earnings Insights Benzinga
04:00PM	Acorda Reports Third Quarter 2020 Financial Results Business Wire
07:38AM	The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga
Nov-02-20 10:17AM	Preview: Acorda Therapeutics's Earnings Benzinga +25.83%
Oct-27-20 07:00AM	Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020 Business Wire
Oct-26-20 12:31PM	Acorda Therapeutics (ACOR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +7.75%
Oct-20-20 11:17AM	Why Acorda's Stock Is Trading Higher Today Benzinga +39.42%
09:47AM	Looking Into Acorda Therapeutics's Return On Capital Employed Benzinga
Sep-29-20 11:25AM	Are Options Traders Betting on a Big Move in Acorda Therapeutics (ACOR) Stock? Zacks -7.04%
Sep-17-20 07:00AM	Aravive Appoints Michael W. Rogers to Board of Directors GlobeNewswire +5.53%
Aug-04-20 06:15PM	Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:20PM	Acorda Therapeutics: Q2 Earnings Insights Benzinga
04:00PM	Acorda Reports Second Quarter 2020 Financial Results Business Wire
Jul-31-20 12:45PM	Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders Business Wire
Jul-28-20 07:00AM	Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020 Business Wire
Jul-08-20 06:40PM	Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)? Insider Monkey
Jun-16-20 04:46PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Acorda Therapeutics, Inc. - ACOR Newsfile
07:30AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Acorda Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors ACCESSWIRE
Jun-12-20 09:36AM	Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally? Zacks
Jun-09-20 10:01AM	Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock? Zacks -8.89%
Jun-04-20 11:31AM	Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound? Zacks
Jun-03-20 09:05AM	Acadia Healthcare Ties Up for Improved Behavioral Services Zacks
May-06-20 07:23PM	DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600 PR Newswire -8.50%
01:27PM	Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y Zacks
May-05-20 06:15PM	Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:00PM	Acorda Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire
Apr-28-20 07:00AM	Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020 Business Wire
Apr-24-20 11:49AM	Acorda (ACOR) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-16-20 05:45PM	Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know Zacks
Apr-07-20 05:50PM	Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know Zacks
12:37PM	Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study Zacks
11:14AM	Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue Zacks
Apr-03-20 08:31AM	Immunomedics (IMMU) in Focus: Stock Moves 5% Higher Zacks
Apr-02-20 10:08AM	Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session Zacks +6.24%
Mar-30-20 08:06AM	New Strong Buy Stocks for March 30th Zacks -5.37%
Mar-17-20 12:00PM	What Makes Acorda (ACOR) a New Buy Stock Zacks
Mar-14-20 11:30AM	Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report? Zacks
Feb-24-20 07:00AM	Acorda Therapeutics to Present at Cowen Annual Health Care Conference Business Wire -9.21%
Feb-18-20 01:44AM	Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -9.50%
Feb-14-20 11:57AM	Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y Zacks -6.77%
Feb-13-20 10:25AM	Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates Zacks
09:15AM	Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4 Zacks
07:00AM	Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-10-20 10:20AM	What's in Store for Acorda (ACOR) This Earnings Season? Zacks
Feb-06-20 12:31PM	Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline Zacks
05:51AM	Acorda Therapeutics, Inc. (NASDAQ:ACOR): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Jan-30-20 07:00AM	Acorda Fourth Quarter/Year End 2019 Update: Webcast/Conference Call Scheduled for February 13, 2020 Business Wire
Jan-24-20 08:54AM	Implied Volatility Surging for Acorda (ACOR) Stock Options Zacks -11.39%
Jan-15-20 07:00AM	Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare Conference Business Wire -8.97%
Jan-08-20 07:00AM	Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire -7.38%
Jan-07-20 10:55AM	Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher Zacks
Jan-03-20 07:55AM	The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger Benzinga +15.82%
Dec-26-19 07:00AM	Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024 Business Wire +43.23%
Dec-23-19 05:30AM	Acorda Therapeutics Announces Private Exchange of $276 Million of Its 1.75% Convertible Senior Notes Due 2021 Business Wire
Dec-12-19 10:31AM	Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR) Insider Monkey
Dec-04-19 11:30AM	Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound? Zacks -11.17%
Dec-02-19 10:22AM	Acorda (ACOR) Down More Than 80% Year to Date: Here's Why Zacks
Nov-27-19 07:00AM	Acorda Therapeutics Elects John Kelley Chair, Board of Directors TEST Business Wire Releases
07:00AM	Acorda Therapeutics Elects John Kelley Chair, Board of Directors Business Wire
Nov-12-19 07:00AM	Acorda Therapeutics Announces Departure of President, International & General Counsel Business Wire -9.59%
Nov-08-19 10:21AM	Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Paid Enough Relative To Peers? Simply Wall St.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience